ABSTRACT
Substantial interest exists in understanding the role of low-disturbance construction methods in mitigating industrial impacts to native grassland soils and vegetation. We assessed soil and vegetation responses to conventional high-disturbance sod-stripping and revegetation on sandy soils, and the alternative practice of low-disturbance access matting to provide a temporary work surface on sandy and loamy soils. Treatments were associated with high-voltage transmission tower construction during 2014 within the Mixedgrass Prairie. High-disturbance sites were hydroseeded in May of 2015, while low-disturbance sites recovered naturally. We assessed soil physical (bulk density, water infiltration) and chemical properties (organic matter, pH, and electrical conductivity) after construction and herbage biomass for three growing seasons. Sod-stripping led to 53% greater soil bulk density and 51% less organic matter than nondisturbed controls, while water infiltration increased by 32% in these high-sand (>80%) soils. In contrast, access matting led to minimal soil property changes regardless of the texture. While total herbage biomass was unaffected by all construction treatments, sod-stripping reduced grass biomass by 80% during the first growing season, which coincided with a 119% increase in forb mass. Root biomass (0-15 cm) also declined 77% with sod-stripping. Vegetation biomass on sites with access matting remained largely unaffected by the disturbance. Overall, low-disturbance construction methods using access matting were more effective than sod-stripping in mitigating the negative impacts of industrial development on Mixedgrass soil properties, as well as vegetation biomass, and are recommended as a best management practice during industrial disturbance.
Subject(s)
Grassland , Soil , Biomass , Poaceae , WaterABSTRACT
The objective of this study was to develop and validate a customized cost-effective single nucleotide polymorphism (SNP) panel for genetic improvement of feed efficiency in beef cattle. The SNPs identified in previous association studies and through extensive analysis of candidate genomic regions and genes, were screened for their functional impact and allele frequency in Angus and Hereford breeds used as validation candidates for the panel. Association analyses were performed on genotypes of 159 SNPs from new samples of Angus (n = 160), Hereford (n = 329), and Angus-Hereford crossbred (n = 382) cattle using allele substitution and genotypic models in ASReml. Genomic heritabilities were estimated for feed efficiency traits using the full set of SNPs, SNPs associated with at least one of the traits (at P ≤ 0.05 and P < 0.10), as well as the Illumina bovine 50K representing a widely used commercial genotyping panel. A total of 63 SNPs within 43 genes showed association (P ≤ 0.05) with at least one trait. The minor alleles of SNPs located in the GHR and CAST genes were associated with decreasing effects on residual feed intake (RFI) and/or RFI adjusted for backfat (RFIf), whereas minor alleles of SNPs within MKI67 gene were associated with increasing effects on RFI and RFIf. Additionally, the minor allele of rs137400016 SNP within CNTFR was associated with increasing average daily gain (ADG). The SNPs genotypes within UMPS, SMARCAL, CCSER1, and LMCD1 genes showed significant over-dominance effects whereas other SNPs located in SMARCAL1, ANXA2, CACNA1G, and PHYHIPL genes showed additive effects on RFI and RFIf. Gene enrichment analysis indicated that gland development, as well as ion and cation transport are important physiological mechanisms contributing to variation in feed efficiency traits. The study revealed the effect of the Jak-STAT signaling pathway on feed efficiency through the CNTFR, OSMR, and GHR genes. Genomic heritability using the 63 significant (P ≤ 0.05) SNPs was 0.09, 0.09, 0.13, 0.05, 0.05, and 0.07 for ADG, dry matter intake, midpoint metabolic weight, RFI, RFIf, and backfat, respectively. These SNPs contributed to genetic variation in the studied traits and thus can potentially be used or tested to generate cost-effective molecular breeding values for feed efficiency in beef cattle.
Subject(s)
Cattle/genetics , Energy Metabolism/genetics , Polymorphism, Single Nucleotide/genetics , Animal Feed , Animals , Body Weight/genetics , Cattle/physiology , Eating/genetics , Energy Metabolism/physiology , Genome , Genomics , Genotype , PhenotypeABSTRACT
Tannins are natural and nutritionally significant components of the diets of browsing ungulates. In trials on supplemented pastures and in drylots, we estimated dry matter intake (DMI), weight gain, and urea N, potassium, cortisol and creatinine in urine of captive white-tailed deer fed pelleted diets that differed only in the respective quebracho tannin (QT) content. The low control, medium and high QT rations were 3.6, 63 and 152 g/kg DM respectively. There was no tannin-free pellet option. Trials were divided into winter pasture, restricted choice and spring growth. In winter pasture trial on pasture using QT, deer reduced QT intake relative to that expected under random foraging. This aversion was also apparent during the spring growth trial. While DMI in the winter pasture trial remained similar among treatments (p > 0.05), averaging 130 g/kg(0.75)/day, deer gained more weight (p < 0.05) when given a choice that included the high QT ration. During subsequent spring growth, DMI and weight gains generally exceeded those of the winter period. Unlike the winter pasture trial, weight gains in spring growth trial were higher (p < 0.05) in the low-control QT treatment. In the restricted choice trial, weight gain was again higher (p < 0.05) for deer fed a low-control QT diet. The urea N/creatinine ratio of deer fed the low-control QT diet (0.0357) was over three times that of deer fed the high QT diet (0.0107). Neither potassium/creatinine nor cortisol/creatinine ratios were affected by diet (p > 0.05). Collectively, these results suggest that although deer do not avoid tannins, and even ingested up to 5% under the choice options in these trials, the effect of tannins on deer performance may vary by season as well as by foraging opportunities.
Subject(s)
Animal Feed/analysis , Deer/growth & development , Diet/veterinary , Tannins/pharmacology , Weight Gain/drug effects , Animal Nutritional Physiological Phenomena , Animals , Dietary Supplements , SeasonsABSTRACT
Little information exists on the performance of deer on alternative forage species in northern temperate environments during summer and fall, the period of inherent maximum growth in deer. In performance and choice experiments, we compared live weight gain (g/kg(0.75)/day), absolute [kg/ha dry matter (DM)] and relative (% DM) herbage utilization, relative preference index (RPI) as well as plant community visitation of white-tailed deer grazing alfalfa (Medicago sativa), birdsfoot trefoil (Lotus corniculatus) or chicory (Cichorium intybus) in north central Alberta, Canada. Herbage phytomass and quality was also measured on the grazed pastures. Alfalfa had higher dry matter yields and crude protein concentrations than chicory and trefoil. Chicory had lower neutral detergent fiber concentrations than the other forages. Tannin concentrations were greatest in birds foot trefoil (nearly 55 g/kg DM), well above those in the other forages (<5 g/kg DM). Live weight gain was similar among deer feeding within the paddocks seeded to birds foot trefoil and chicory, and more than two times higher (p < 0.05) than deer feeding in paddocks seeded to alfalfa. Deer spent more grazing time (about 40%) on chicory pastures than on alfalfa and birds foot trefoil pastures. RPI values were greatest for birds foot trefoil at 2.11, intermediate for chicory at 1.40, and lowest for alfalfa at <0.60. Absolute herbage utilization remained similar (p > 0.05) among the three forage species. In contrast, relative herbage utilization was greater from birds foot trefoil (52% DM) than chicory (40% DM) or alfalfa (25% DM). These results suggest that the use of alfalfa with other alternative forages may prove beneficial to deer production, rather than using alfalfa pasture alone.
Subject(s)
Cichorium intybus , Deer/physiology , Food Preferences , Lotus , Medicago sativa , Alberta , Animal Feed , Animal Nutritional Physiological Phenomena , Animals , Diet , Weight GainABSTRACT
OBJECTIVE: Calcitonin gene-related peptide (CGRP) is a regulatory peptide encoded by the calcitonin gene. CGRP is expressed in increased amounts by the cells of medullary thyroid carcinomas and has been demonstrated by immunohistochemistry to occur in neuroendocrine cells and nerve fibres of lung tissue. MEASUREMENTS: Serum CGRP levels were measured in patients with small cell lung carcinomas before treatment (n = 74) and immediately before the second course of chemotherapy (n = 30). In-situ hybridization and immunohistochemistry were performed on tumour tissue and CGRP was extracted from two tumours and characterized by gel chromatography and high pressure liquid chromatography. RESULTS: Serum CGRP levels were elevated in small cell lung carcinomas when compared with healthy controls of similar age and sex (median values 55.0 vs 36.6 pmol/l, P < 0.001), and 27% had levels above the upper normal range. Serum CGRP levels decreased following the initial course of chemotherapy (P < 0.05) but remained elevated when compared to the controls (P < 0.001). In-situ hybridization for CGRP mRNA was positive in three of 17 tumours and immunohistochemistry was positive in seven of 31 tumours investigated. CGRP immunoreactivity extracted from two tumours was characterized by gel chromatography and high pressure liquid chromatography. A major part of the immunoreactivity was demonstrated to represent the intact molecule. CONCLUSIONS: We found that patients with small cell lung carcinomas had elevated concentration of serum calcitonin gene-related peptide but only 27% had values above the upper normal range. Serum CGRP is therefore of limited value as a tumour marker. Intact CGRP can be extracted from tumour tissue, but in-situ hybridization and immunohistochemistry showed positive reactions in only a few of the tumours investigated. The elevated serum CGRP levels are therefore likely to be largely of extratumoral origin.
Subject(s)
Biomarkers, Tumor/blood , Calcitonin Gene-Related Peptide/blood , Carcinoma, Small Cell/blood , Lung Neoplasms/blood , Adult , Aged , Amino Acid Sequence , Calcitonin Gene-Related Peptide/chemistry , Carcinoma, Small Cell/chemistry , Carcinoma, Small Cell/drug therapy , Chromatography, Gel , Chromatography, High Pressure Liquid , Female , Humans , Immunohistochemistry , In Situ Hybridization , Lung Neoplasms/chemistry , Lung Neoplasms/drug therapy , Male , Middle Aged , Molecular Sequence DataABSTRACT
The epipodophyllotoxin derivatives teniposide and etoposide have been under clinical investigation for over 15 years. Although etoposide has been established as one of the most active compounds in the treatment of small cell lung cancer (SCLC), teniposide has received little attention. The results of seven phase II studies evaluating response rate and duration of response to teniposide in 10 previously treated and 102 untreated patients showed response rates of 21% and 58%, respectively. The most frequently used dosage schedule was 60 mg/m2 intravenously daily for 5 days every 3 weeks. The following are factors influencing the response rate and duration of response to teniposide: performance status; prior weight loss; prior chemotherapy exposure, including prior treatment with etoposide; stage; and effectiveness of prior chemotherapy, including time from last administration. Preliminary analyses from a study comparing the efficacy of teniposide with that of etoposide suggest that teniposide may be more effective in previously untreated patients with SCLC who are 70 years of age or older. The preliminary data, however, indicate that equivalent doses of teniposide cause more cases of leukopenia than etoposide. Before a final conclusion can be drawn, the results from an ongoing study using teniposide and etoposide at equitoxic doses must be evaluated.
Subject(s)
Carcinoma, Small Cell/drug therapy , Lung Neoplasms/drug therapy , Teniposide/therapeutic use , Clinical Trials, Phase II as Topic , Humans , Teniposide/administration & dosageABSTRACT
A randomized study comparing teniposide (VM-26) and etoposide (VP-16) was performed to investigate whether there are any differences in the activity and toxicity of these two analogs in small-cell lung cancer (SCLC). Only previously untreated patients with SCLC were included; 46 and 48 patients receiving VP-16 and VM-26, respectively, are assessable for response. There were no differences between the two groups with respect to extent of disease, median age, and performance status (PS). The initial doses were for both compounds 70 mg/m2 intravenously (IV) daily for 5 days every 3 weeks. After inclusion of 25 patients in the study, the doses were increased to 80 mg/m2 for VM-26 and 90 mg/m2 for VP-16 because of differences in toxicity. VM-26 caused more hematologic toxicity than VP-16 throughout the study. The overall responses (complete response [CR] plus partial response [PR]) were 65% for VP-16 and 71% for VM-26, with CR occurring in 24% and 23%, respectively, for the two compounds. Median survival was 8.5 months for VP-16-treated patients versus 11.3 months for VM-26-treated patients (P = .58). It is concluded that both VP-16 and VM-26 are highly active single agents in SCLC.
Subject(s)
Carcinoma, Small Cell/drug therapy , Etoposide/therapeutic use , Lung Neoplasms/drug therapy , Teniposide/therapeutic use , Aged , Aged, 80 and over , Drug Administration Schedule , Etoposide/adverse effects , Female , Humans , Infusions, Intravenous , Male , Prospective Studies , Teniposide/adverse effectsABSTRACT
Many small-cell lung cancers (SCLCs) produce gastrin-releasing peptides (GRPs) (mammalian bombesin) but the plasma concentration of GRP is rarely elevated, possibly because of its rapid elimination. We developed a radioimmunoassay for the C-terminal flanking peptide of proGRP and measured its concentration in plasma from 71 patients with SCLC, in 27 healthy subjects and in 49 patients with other diseases including lung carcinomas. In addition, we studied the molecular size of immunoreactive C-flanking peptide in two SCLC cell lines and in plasma from SCLC patients. The concentration of immunoreactive C-flanking peptide in normal subjects and in control patients did not exceed 10 pmol/L and 26 pmol/L, whereas 72% of the SCLC patients had C-flanking peptide concentrations above 10 pmol/L. In patients with extensive disease (n = 35) the median concentration was 71 pmol/L (range, 10 to 940). ProGRP C-flanking peptide levels paralleled the clinical course in 12 patients. The molecule(s) responsible for the immunoreactivity had a molecular size of about 8 to 10 kd in both patient plasma and tumor cell lines, suggesting that the measured peptide(s) represented major fragment(s) if not the entire C-flanking peptide of proGRP. Thus this peptide(s) seems to be a useful marker for SCLC.
Subject(s)
Carcinoma, Small Cell/blood , Lung Neoplasms/blood , Peptides/blood , Biomarkers, Tumor , Chromatography, Gel , Gastrin-Releasing Peptide , Humans , Molecular Weight , Peptide Fragments/blood , Protein Precursors/blood , Radioimmunoassay , Tumor Cells, CulturedABSTRACT
Brequinar, DUP 785, is a substituted 4-quinoline carboxylic acid derivative which in preclinical studies has shown broad antitumor activity. It is a novel antimetabolite blocking pyrimidine nucleotide synthesis. In a clinical phase I study, 83 patients were treated on a weekly schedule and 18 patients on a biweekly schedule. The drug was given intravenously as a short infusion. Three patients were entered on each dose level from a starting dose of 6 mg/m2 up to 2600 mg/m2 weekly. The dose ranges on a biweekly schedule were 500-850 mg/m2. There was no dose escalation in individual patients. Pharmacokinetic studies were performed in 19 patients on a weekly schedule and in two patients on a biweekly schedule. A biphasic decay in plasma was observed with a median half life of 10 h (5.1-23.4). The main dose-limiting toxicity was thrombocytopenia. Of non-hematologic side-effects, stomatitis/mucositis occurred frequently. Skin eruptions occurred rarely, but were a major problem when found. All side-effects were fully reversible; there were no signs of cumulative toxicity. Antitumor activity was observed in one patient with a lung metastasis from a bladder cancer and in a patient with an unknown primary tumor. The recommended doses for phase II trials with DUP 785 are: 1500-2000 mg/m2 on a weekly schedule and 500-750 mg/m2 on a biweekly schedule dependent on status before treatment.
Subject(s)
Antineoplastic Agents/therapeutic use , Biphenyl Compounds/therapeutic use , Neoplasms/drug therapy , Adolescent , Adult , Aged , Biphenyl Compounds/administration & dosage , Biphenyl Compounds/pharmacokinetics , Drug Administration Schedule , Drug Evaluation , Female , Genital Neoplasms, Female/drug therapy , Humans , Lung Neoplasms/drug therapy , Male , Middle Aged , Platelet Count , Urologic Neoplasms/drug therapyABSTRACT
Brequinar sodium (NSC 368390; DUP 785) is a new inhibitor of pyrimidine de novo biosynthesis which has completed Phase I clinical trials within the framework of the Early Clinical Trials Group of the European Organization for Research and Treatment of Cancer (EORTC). The main side effects of this compound are myelosuppression, nausea and vomiting, stomatitis and/or mucositis, and skin rash. In this report, the authors describe the pattern of mucocutaneous side effects of Brequinar sodium in patients who received the drug by four different schedules: (1) short-term intravenous (IV) infusion every 3 weeks; (2) weekly; (3) twice weekly; and (4) five times daily every 4 weeks. Mucocutaneous toxicities of Brequinar sodium included mainly cytotoxic reactions (stomatitis and/or mucositis and skin rash). However, rare episodes of local reactions (phlebitis at the site of injection), photosensitivity reactions (to sun light), angioneurotic edema, and localized secondary hyperpigmentation of the inflamed skin also occurred. Stomatitis and/or mucositis appeared to be dose-dependent and schedule-dependent. The skin rash consisted of a drug-induced toxic dermatitis which occurred mostly at the highest dose levels. Initial recommendations for the management of mucocutaneous toxicities of Brequinar sodium during Phase II trials are discussed.
Subject(s)
Antineoplastic Agents/adverse effects , Biphenyl Compounds/adverse effects , Drug Eruptions/etiology , Aged , Antineoplastic Agents/administration & dosage , Biphenyl Compounds/administration & dosage , Diarrhea/chemically induced , Drug Administration Schedule , Drug Evaluation , Female , Humans , Male , Middle Aged , Mucous Membrane/drug effects , Nausea/chemically induced , Neoplasms/drug therapy , Skin Ulcer/etiology , Stomatitis/chemically induced , Vomiting/chemically inducedABSTRACT
Creatine kinase (CK-BB), neuron specific enolase (NSE), ACTH, calcitonin, serotonin and gastrin releasing peptide (GRP) were measured in serum or plasma before and immediately after initiation of treatment in patients with small cell lung cancer (SCC). Pretherapeutic elevated concentrations of CK-BB were found in 82% of extensive disease patients and in 50% of patients with local disease. NSE was raised in 72% with extensive disease versus 14% of patients with local disease. Calcitonin and ACTH were raised in 27% and 28%, respectively, in all patients without significant difference between extensive and local disease patients. Serotonin was generally overall elevated in 10% and GRP in 7% but elevations were seen only in patients with extensive disease. Out of the four most frequently elevated substances at least one marker was elevated in 80% of all the patients, including 91% in extensive stage patients and 71% in limited stage patients. Frequent initial monitoring of the substances showed an increase in the concentrations of pretherapeutic elevated CK-BB and NSE on day 1 or 2 followed by a sharp decrease within 1 week. These changes were correlated to objective clinical response determined within 4-8 weeks. The results indicate that serum CK-BB and NSE are potential markers for SCC at the time of diagnosis and that changes in the concentrations during the first course of cytostatic therapy are promising as biochemical tests for early detection of response to chemotherapy.
Subject(s)
Biomarkers, Tumor/blood , Carcinoma, Small Cell/blood , Lung Neoplasms/blood , Adrenocorticotropic Hormone/blood , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Calcitonin/blood , Carcinoma, Small Cell/drug therapy , Creatine Kinase/blood , Gastrin-Releasing Peptide , Gastrointestinal Hormones/blood , Humans , Lung Neoplasms/drug therapy , Peptides/blood , Phosphopyruvate Hydratase/blood , Serotonin/blood , Time FactorsABSTRACT
The quianazoline antifolate N10-propargyl-5,8-dideazafolic acid (ICI 155,387), an inhibitor of thymidylate synthetase (TS), was evaluated for clinical toxicity in a phase I trial. The compound was given once every week as a bolus injection. Fourteen patients with advanced cancer were treated at doses of 10-30 mg/m3. Four patients from the lowest to the highest dose developed severe renal toxicity, detected by a reversible decrease in the Cr-EDTA clearance. Hepatotoxicity was observed with transient elevations of alanine aminotransferase (ALT) in 10 patients and alkaline phosphatase in nine patients. Neither the incidence nor the severity of these toxicities was dose related. Two patients developed feelings of fatigue, which in one patient coincided with a decrease in Cr-EDTA clearance. No myelotoxicity, dermatological, gastrointestinal toxicity or mucositis was seen. No tumour responses due to ICI 155,387 occurred. The severity and the erratic nature of the renal side-effects suggest that this schedule cannot be recommended for further development of this compound in Phase II trials.
Subject(s)
Folic Acid/analogs & derivatives , Neoplasms/drug therapy , Quinazolines/therapeutic use , Adult , Aged , Dose-Response Relationship, Drug , Drug Evaluation , Folic Acid/adverse effects , Folic Acid/therapeutic use , Humans , Middle Aged , Quinazolines/adverse effectsABSTRACT
TCNU (1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-1-nitrosour ea) is a newly developed water-soluble nitrosourea based on the endogenous aminoethanesulphonic acid taurine. TCNU was in an extended phase I trial given orally every 4-8 weeks using a stepwise dose escalation from 20 to 170 mg/m2. One hundred and thirty-nine patients received a total of 323 courses. Minor haematologic toxicity was observed in 12 patients treated at dose levels less than 70 mg/m2. Thrombocytopenia WHO grades 1-4 occurred in 43% (55/127) and leucopenia WHO grades 1-3 in 45% (57/127) of the patients treated at dose levels greater than or equal to 70 mg/m2. Nausea and vomiting was recorded in about half the patients despite the use of metoclopramide. At the initial dose level 41 patients received greater than or equal to 3 courses of TCNU. Cumulative leucopenia and thrombocytopenia occurred in 3/41 and in 12/41 patients, respectively, while reversible hepatotoxicity was observed in two patients. Antitumour activity was observed in patients with advanced squamous cell, adeno- and large cell carcinoma of the lung. The recommended starting doses for phase II trials with TCNU are as follows: heavily pretreated patients 90 mg/m2, minimally/-moderately pretreated patients 110 mg/m2 and previously untreated patients 130 mg/m2 with TCNU given every 4-5 weeks, the repeated doses and intervals being adjusted to individual tolerance.
Subject(s)
Antineoplastic Agents/therapeutic use , Neoplasms/drug therapy , Nitrosourea Compounds/therapeutic use , Taurine/analogs & derivatives , Adolescent , Adult , Aged , Antineoplastic Agents/adverse effects , Dose-Response Relationship, Drug , Drug Evaluation , Hematologic Diseases/chemically induced , Humans , Middle Aged , Nitrosourea Compounds/adverse effects , Prohibitins , Taurine/adverse effects , Taurine/therapeutic useABSTRACT
Two hundred seventy-nine patients with previously untreated nonresectable adenocarcinoma of the lung (ACL) entered a prospective randomized trial, comparing vindesine (VDS) to a combination of lomustine (CCNU), cyclophosphamide (CTX), and methotrexate (MTX), and to a regimen including all four drugs. Response assessment was possible in 218 patients, while 259 were evaluable for survival. Response rates were similar (22%, 23%, and 27%, respectively) as were median durations of response (15 weeks overall) and survival (29 weeks overall). Patients with dose-limiting toxicity had significantly higher response rate and longer survival than patients without toxicity. The major toxicity was peripheral neuropathy with VDS treatment and myelosuppression with the other two regimens. The VDS single-agent activity in ACL was confirmed, but addition of VDS to the three-drug regimen did not increase activity. Future studies of VDS in combination with other active agents, and comparison to a matched control group on supportive care, are indicated.
Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lung Neoplasms/drug therapy , Vindesine/therapeutic use , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bone Marrow Diseases/chemically induced , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Drug Evaluation , Female , Humans , Lomustine/administration & dosage , Lomustine/adverse effects , Male , Methotrexate/administration & dosage , Methotrexate/adverse effects , Middle Aged , Peripheral Nervous System Diseases/chemically induced , Random Allocation , Vindesine/adverse effectsABSTRACT
In order to evaluate the regional lung function in patients with small cell lung cancer with long-term survival, we measured the regional lung function in 17 patients. We studied the patients with 81m-krypton ventilation scans and 99m-technetium perfusion scans, as well as measurements of static lung volumes (VC, RV, TLC), flow volume indices (FEV1, FVC, MEF50), and carbon monoxide diffusing capacity (DLCO). We found both the ventilation and the perfusion of the affected lung to be slightly but significantly lower (P less than 0.05), while no obvious ventilation or perfusion defects could be identified at the former tumor site. The static volumes of the lungs, the FVC and the FEV1 were within predicted normal values, while a significant decrease was seen in the PEF, MEF50, and DLCO. It is concluded that patients with small cell lung cancer who obtain complete remission with normalization of the chest X-ray and long-term survival after 18 months of intensive chemotherapy also have a nearly normal lung function.
Subject(s)
Carcinoma, Small Cell/physiopathology , Lung Neoplasms/physiopathology , Respiratory Function Tests , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Small Cell/diagnostic imaging , Carcinoma, Small Cell/drug therapy , Humans , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/drug therapy , Lung Volume Measurements , Middle Aged , Pulmonary Gas Exchange , Radionuclide Imaging , Remission Induction , Time FactorsSubject(s)
Aminoglutethimide/adverse effects , Breast Neoplasms/drug therapy , Diuretics/adverse effects , Hyponatremia/chemically induced , Aged , Aminoglutethimide/administration & dosage , Diuretics/administration & dosage , Drug Interactions , Drug Therapy, Combination , Female , Humans , Hydrocortisone/administration & dosage , Sodium/blood , Sodium/urineABSTRACT
Teniposide, VM-26 (Vumon), was administered in a dose of 60 mg/m2 on days 1 to 5 every third week to 36 patients with histologically confirmed small-cell lung cancer. None had previously received chemotherapy or radiotherapy. The median age was 73 years (range, 52 to 79). Thirty-three patients were evaluable; 21 of these had local disease. Five patients had bone marrow metastases, four had liver involvement, and one CNS metastases. All patients had a performance status less than or equal to 2 before the start of treatment. Thirty patients obtained a response (90%), ten of whom had a complete remission (30%). The median duration of remission was 8+ months (range, 1.1 to 17+ months), whereas the median survival was 8.7 months (range, 1.9 to 20 months). Toxicity was primarily hematologic, with leukopenia the only dose-limiting effect. Besides alopecia, all other side effects were minimal including nausea and vomiting. We find these results provocative in regard to the response rate and the duration of response obtained as well as in reference to the dismal results that prior investigations in previously treated patients have shown. These data may indicate the need for reconsideration of the usual strategy for performing phase II trials.
Subject(s)
Carcinoma, Small Cell/drug therapy , Lung Neoplasms/drug therapy , Podophyllotoxin/analogs & derivatives , Teniposide/toxicity , Aged , Drug Administration Schedule , Drug Evaluation , Humans , Middle Aged , Neoplasm Metastasis , Teniposide/administration & dosage , Teniposide/therapeutic useABSTRACT
The effect of doxorubicin and cyclophosphamide in the treatment of diffuse, malignant pleural mesothelioma was evaluated in a randomized study. All patients were treated on an outpatient basis and none had previously received antineoplastic treatment. All patients had a measurable lesion other than pleural effusion. The treatment consisted of doxorubicin at a dose of 60 mg/m2 every 3 weeks, to a total dose of 550 mg/m2, or cyclophosphamide at a dose of 1500 mg/m2 every 3 weeks for 1 year. At disease progression the treatment was changed to the alternate drug. The dose was increased or decreased according to hematologic effects. Thirty of 32 patients were evaluable for response. Remissions were not achieved in any patient. During treatment with doxorubicin, none of the patients developed cardiotoxicity, while one patient developed hemorrhagic cystitis during treatment with cyclophosphamide. Sepsis or bleeding was not observed in either of the treatment arms. Thus, the trial showed no antineoplastic activity of either doxorubicin or cyclophosphamide in the treatment of malignant pleural mesothelioma.